EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives

Michiel Vlaming, Margreet G E M Ausems, Gina Schijven, Inge M van Oort, C Marleen Kets, Fenne L Komdeur, Lizet E van der Kolk, Rogier A Oldenburg, Rolf H Sijmons, Lambertus A L M Kiemeney, Eveline M A Bleiker

Familial Cancer · 2024

DOI: 10.1007/s10689-024-00377-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Familial Cancer, 2024. Verfasst von Michiel Vlaming und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Heidelberglaan 100, CX Utrecht, 3…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Genetic Testing, Germ-Line Mutation, Genetic Predisposition to Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Some patients with metastatic prostate cancer carry a pathogenic germline variant (PV) in a gene, that is mainly associated with an increased risk of breast cancer in women. If they test positive for such a PV, prostate cancer patients are encouraged to disclose the genetic test result to relatives who are at risk in case the carrier status changes the relatives’ medical care. Our study aimed to investigate how men who learned they carry a PV in BRCA1, BRCA2, PALB2, CHEK2 or ATM disclosed their carrier status to at-risk relatives and to assess the possible psychological burden for the carrier and their perception of the burden for relatives. In total, 23 men with metastatic prostate cancer carrying a PV completed the IRI questionnaire about family communication; 14 also participated in a semi-structured interview. Patients felt highly confident in discussing the genetic test result with relatives. The diagnosis of prostate cancer was experienced as a burden, whereas being informed about genetic testing results did in most cases not add to this burden. Two patients encountered negative experiences with family communication, as they considered the genetic test result to be more urgent than their relatives. This mixed-methods study shows that metastatic prostate cancer patients with a PV in genes mainly associated with increased risk of breast cancer feel well-equipped to communicate about this predisposition in their families. Carriers felt motivated to disclose their genetic test result to relatives. Most of them indicated that the disclosure was not experienced as a psychological burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGenetic TestingGerm-Line MutationGenetic Predisposition to DiseaseHumansMaleMiddle AgedAgedBRCA2 ProteinDisclosureFanconi Anemia Complementation Group N ProteinBRCA1 ProteinCheckpoint Kinase 2Breast NeoplasmsFamilyFemaleAtaxia Telangiectasia Mutated ProteinsAdult

Stichwörter der Autor:innen

Breast cancerFamily communicationGenetic testingMetastatic prostate cancerPsychosocial

Substanzen

BRCA2 ProteinPALB2 protein, humanBRCA2 protein, humanFanconi Anemia Complementation Group N ProteinBRCA1 ProteinBRCA1 protein, humanCHEK2 protein, humanCheckpoint Kinase 2ATM protein, humanAtaxia Telangiectasia Mutated Proteins

Autor:innen und Institutionen

  • Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Heidelberglaan 100, CX Utrecht, 3584, The Netherlands.
  • Department of Urology, Radboud University Medical Center, Geert Grooteplein Zuid 10, GA Nijmegen, 6525, The Netherlands.
  • Department of Human Genetics, Radboud University Medical Center, Geert Grooteplein Zuid 10, GA Nijmegen, 6525, The Netherlands.
  • Department of Human Genetics, Amsterdam University Medical Centers, Meibergdreef 9, AZ Amsterdam, 1105, The Netherlands.
  • Department of Clinical Genetics, the Netherlands Cancer Institute, Plesmanlaan 121, CX Amsterdam, 1066, The Netherlands.
  • Department of Clinical Genetics, Erasmus Medical Center, Dr. Molewaterplein 40, GD Rotterdam, 3015, The Netherlands.

Förderung

  • KWF Kankerbestrijding

Zitieren

APA

Vlaming, M., Ausems, M. G. E. M., Schijven, G., van Oort, I. M., Kets, C. M., Komdeur, F. L., van der Kolk, L. E., Oldenburg, R. A., Sijmons, R. H., Kiemeney, L. A. L. M., & Bleiker, E. M. A. (2024). Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives. Familial Cancer. https://doi.org/10.1007/s10689-024-00377-0

Vancouver

Vlaming M, Ausems MGEM, Schijven G, van Oort IM, Kets CM, Komdeur FL, et al. Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives. Familial Cancer. 2024. doi:10.1007/s10689-024-00377-0

BibTeX
@article{Vlaming2024,
  author = {Vlaming, Michiel and Ausems, Margreet G E M and Schijven, Gina and van Oort, Inge M and Kets, C Marleen and Komdeur, Fenne L and van der Kolk, Lizet E and Oldenburg, Rogier A and Sijmons, Rolf H and Kiemeney, Lambertus A L M and Bleiker, Eveline M A},
  title = {Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives},
  journal = {Familial Cancer},
  year = {2024},
  doi = {10.1007/s10689-024-00377-0}
}
Kostenlos starten →